Suppr超能文献

运动皮层刺激治疗肌萎缩侧索硬化症:一项双盲安慰剂对照研究。

Motor cortex stimulation for ALS: a double blind placebo-controlled study.

作者信息

Di Lazzaro Vincenzo, Pilato Fabio, Profice Paolo, Ranieri Federico, Musumeci Gabriella, Florio Lucia, Beghi Ettore, Frisullo Giovanni, Capone Fioravante, Sabatelli Mario, Tonali Pietro A, Dileone Michele

机构信息

Institute of Neurology, Università Cattolica, 00168 Rome, Italy.

出版信息

Neurosci Lett. 2009 Oct 16;464(1):18-21. doi: 10.1016/j.neulet.2009.08.020. Epub 2009 Aug 12.

Abstract

Preliminary data suggest that repetitive transcranial magnetic stimulation (rTMS) of the brain may produce a modest slowing of disease progression in amyotrophic lateral sclerosis (ALS). The present study was designed to test the hypothesis that rTMS given as continuous theta burst stimulation (cTBS), repeated monthly for one year, would affect ALS progression. We performed a double blind, placebo-controlled trial. Twenty patients with ALS were randomly allocated to blinded real or placebo stimulation. cTBS of the motor cortex was performed for five consecutive days every month for one year. Primary outcome was the rate of decline as evaluated with the revised ALS functional rating scale (ALSFRS-R). Treatment was well tolerated. There was no significant difference in the ALSFRS-R score deterioration between patients treated with real or placebo stimulation. ALSFRS-R mean scores declined from 32.0 (SD 7.1) at study entry to 23.1 (SD 6.3) at 12 months in patients receiving real cTBS and from 31.3 (SD 6.9) to 21.2 (SD 6.0) in those receiving placebo stimulation. Although cTBS proved a safe procedure, on the basis of the present findings a larger randomized confirmatory trial seems unjustified in ALS patients, at least in advanced stage of the disease.

摘要

初步数据表明,对大脑进行重复经颅磁刺激(rTMS)可能会使肌萎缩侧索硬化症(ALS)的疾病进展略有减缓。本研究旨在验证以下假设:以连续θ波爆发刺激(cTBS)形式进行的rTMS,每月重复一次,持续一年,会影响ALS的进展。我们进行了一项双盲、安慰剂对照试验。20例ALS患者被随机分配接受盲法真实刺激或安慰剂刺激。对运动皮层进行cTBS,每月连续5天,持续一年。主要结局是用修订的ALS功能评定量表(ALSFRS-R)评估的下降率。治疗耐受性良好。接受真实刺激或安慰剂刺激的患者在ALSFRS-R评分恶化方面没有显著差异。接受真实cTBS的患者的ALSFRS-R平均评分从研究开始时的32.0(标准差7.1)降至12个月时的23.1(标准差6.3),接受安慰剂刺激的患者从31.3(标准差6.9)降至21.2(标准差6.0)。尽管cTBS被证明是一种安全的程序,但基于目前的研究结果,至少在疾病晚期的ALS患者中,进行更大规模的随机验证性试验似乎没有必要。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验